ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated October 4, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI(LODR), 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Increase In Volume
This has reference to your email dated October 9, 2023 bearing reference no. L/SURV/ONL/PV/KA/2023-2024/359 on the captioned subject. We wish to inform you that we have no information/ announcement including pending announcement which in the Company''s opinion may have a bearing on the price/ volume behaviour in the scrip. We thank you for drawing our attention and assure you of Company''s continued adherence to its obligation under the SEBI(LODR) Regulations, 2015. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification sought from AstraZeneca Pharma India Ltd
The Exchange has sought clarification from AstraZeneca Pharma India Ltd on October 9, 2023, with reference to Movement in Volume.The reply is awaited. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Determination Of Materiality - Details Of Key Managerial Personnel
We wish to inform you that as required under the Regulation 30(5) of SEBI (LODR), 2015, the contact details of the Key Managerial Personnel authorised jointly and/or severally to determine the materiality of an event and/or information to the Stock Exchanges(s) are enclosed.
AstraZeneca India falls 0.6% despite a new CFO and nod to drug imports
AstraZeneca Pharma India shares slipped 0.6% in trade on October 3. The firm appointed a new CFO and received approval from the CDSCO to import a new drug. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Permission To Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab (Synagis)
AstraZeneca Pharma India Limited receives permission to Import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Palivizumab (Synagis). ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 and as mentioned in our letter dated May 30, 2023 to the stock exchanges, we wish to inform that Mr. Rajesh Marwaha (DIN: 01458768) shall retire from the office of Chief Financial Officer and Whole-time Director of the Company with effect from the closing of business hours on September 30, 2023. Further, as mentioned in our letter dated May 30, 2023 to the stock exchanges, we wish to inform that Mrs. Bhavana Agrawal shall hold the office of Chief Financial Officer of the Company with effect from October 1, 2023. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI(LODR) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management Personnel
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Praveen Akkinepally as the Business Unit Head - Oncology with effect from November 1, 2023.